glp 1 agonist liraglutide Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice GLP-1 Agonists: A Breakthrough in

Therapy with GLP-1RA should therefore start with low doses that can be uptitrated (33, 34)

Exenatide use and incidence of pancreatic and thyroid cancer: a retrospective cohort study

As a result, the absence of increased cancer incidence in short-to mid-term follow-up cannot be equated with long-term oncological safety

March 2, 2026: Gastrointestinal Lawsuits Involving Trulicity, Other GLP-1s Increase in March Eli Lilly and one other drug company are facing 3,363 lawsuits in a consolidated MDL, in which plaintiffs accuse the companies of failing to warn patients about the gastrointestinal risks of taking Trulicity and other GLP-1s

The exciting beyond obesity frontier for GLP-1 drugs is their potential to treat conditions where inflammation, or other non-obesity factors, are the primary cause

C., Forst T., Aronson R., et al